Bank Julius Baer & Co
VRTX icon

Bank Julius Baer & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Bank Julius Baer & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142M Sell
317,406
-48,935
-13% -$22.8M 0.43% 56
2025
Q4 		$166M Sell
366,341
-10,154
-3% -$4.38M 0.46% 55
2025
Q3 		$147M Sell
376,495
-14,881
-4% -$6.22M 0.42% 64
2025
Q2 		$174M Sell
391,376
-6,655
-2% -$3.07M 0.52% 55
2025
Q1 		$194M Buy
398,031
+29,064
+8% +$13.5M 0.63% 44
2024
Q4 		$159M Buy
368,967
+33,322
+10% +$15.4M 0.49% 49
2024
Q3 		$178M Buy
335,645
+322,142
+2,386% +$155M 0.6% 44
2024
Q2 		$5.88M Sell
13,503
-272,605
-95% -$118M 0.02% 177
2024
Q1 		$119M Buy
286,108
+10,735
+4% +$4.54M 0.46% 59
2023
Q4 		$112M Buy
275,373
+89,743
+48% +$33.2M 0.47% 60
2023
Q3 		$64.6M Buy
185,630
+13,969
+8% +$4.89M 0.38% 69
2023
Q2 		$60.4M Buy
171,661
+204
+0.1% +$68.7K 0.36% 68
2023
Q1 		$54M Buy
171,457
+1,087
+0.6% +$326K 0.34% 71
2022
Q4 		$49.2M Buy
170,370
+162,295
+2,010% +$49.5M 0.34% 70
2022
Q3 		$2.34M Buy
8,075
+3,767
+87% +$1.08M 0.02% 191
2022
Q2 		$1.21M Buy
4,308
+1,189
+38% +$318K 0.01% 252
2022
Q1 		$814K Buy
3,119
+2,659
+578% +$631K ﹤0.01% 303
2021
Q4 		$101K Sell
460
-4,515
-91% -$878K ﹤0.01% 604
2021
Q3 		$902K Buy
4,975
+2,093
+73% +$409K 0.01% 345
2021
Q2 		$581K Buy
2,882
+703
+32% +$147K ﹤0.01% 429
2021
Q1 		$468K Sell
2,179
-14,069
-87% -$3.09M ﹤0.01% 459
2020
Q4 		$3.84M Buy
16,248
+7,852
+94% +$1.8M 0.03% 210
2020
Q3 		$2.23M Buy
8,396
+2,220
+36% +$612K 0.02% 214
2020
Q2 		$1.79M Sell
6,176
-851
-12% -$231K 0.02% 206
2020
Q1 		$1.67M Buy
+7,027
New +$1.61M 0.04% 170

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank Julius Baer & Co's VRTX Position: Q1 2026 in Review

Bank Julius Baer & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, selling an estimated $22.8M and leaving 317,406 shares worth $142M. The position accounts for 0.43% of the portfolio, ranked #56.

Bank Julius Baer & Co first reported a position in VRTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $194M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Bank Julius Baer & Co held 317,406 shares of Vertex Pharmaceuticals worth $142M as of Q1 2026.
  • Bank Julius Baer & Co sold 48,935 Vertex Pharmaceuticals shares in Q1 2026, an estimated $22.8M.
  • Vertex Pharmaceuticals made up 0.43% of Bank Julius Baer & Co's portfolio in Q1 2026, its #56 holding.
  • Bank Julius Baer & Co first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Bank Julius Baer & Co's Vertex Pharmaceuticals position peaked at $194M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Bank Julius Baer & Co's 13F filing for Q1 2026, filed 5 May 2026.